OGN241220P17500
- 1.97
- +0.07+3.68%
Organon & Co Newsroom
Merck-marketed Asthma Drug Linked to Psychiatric Issues: Report
US Manufacturing Index Rises To 43, Highest Since 2020
Organon & Co To Go Ex-Dividend On November 12th, 2024 With 0.28 USD Dividend Per Share
Looking Into Organon's Recent Short Interest
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Organon & Co Shares Are Trading Lower After the FDA Extended the Target Action Date of Its Review for the Company's Supplemental New Drug Application for Vtama Cream.
Organon: FDA Extends Vtama Atopic-Dermatitis Review to March
Express News | Organon & Co - FDA Raises No Safety or Efficacy Concerns for Vtama
Express News | Organon & Co - New Target Date for Vtama Review Is March 12, 2025
Express News | Organon & Co - FDA Extends Review Date for Organon's Vtama Cream
Update on FDA Review of VTAMA (Tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Express News | Update on FDA Review of Vtama® (Tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
BofA Securities Maintains Organon & Co(OGN.US) With Sell Rating
Evercore Maintains Organon & Co(OGN.US) With Buy Rating
Organon & Co | 10-Q: Q3 2024 Earnings Report
Express News | Organon & Co. : Morgan Stanley Cuts Target Price to $17.00 From $18.00
Piper Sandler Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $24
Organon & Co. (OGN) Q3 2024 Earnings Call Transcript Summary
Organon & Co. (OGN) Q3 2024 Earnings Call Transcript